Using the drop-down menu below, read about highlighted scientific news for patients from ASCO's Annual Meetings, Symposia, and medical journals for the past three years. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
This includes ASCO’s Journal of Clinical Oncology and its scientific meetings, including the ASCO Annual Meeting, a five-day meeting held each May/June. To read the Annual Meeting summaries compiled into a yearly newsletter, you can also review Research Round Up: News for Patients from the ASCO Annual Meeting. Don’t forget to check out audio podcasts and videos about this news, as well. And a list of upcoming Symposia can be found here. And, in addition to the highlighted studies below, thousands of scientific abstracts are released each year at different ASCO meetings. To search the entire collection of meeting abstracts, visit ASCO's website.
A long-term study shows that a combination of bendamustine (Treanda) and rituximab (Rituxan) keeps two uncommon types of non-Hodgkin lymphoma (NHL), indolent (slow-growing) lymphoma and mantle cell lymphoma, from worsening longer than standard chemotherapy. Bendamustine and rituximab are drugs called targeted therapies. Targeted therapy is a treatment that targets the cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival.
A long-term study comparing two common hormone therapy schedules showed that intermittent (short breaks in treatment) hormone therapy is less effective than continuous (no breaks in treatment) hormone therapy for men with hormone-sensitive prostate cancer with minimal disease spread (cancer that has not spread beyond the spine, pelvis, and lymph nodes). Hormone-sensitive prostate cancer is cancer that uses male sex hormones called androgens, such as testosterone, to grow and spread. Hormone therapy, also called androgen ablation or androgen-deprivation therapy, lowers levels of androgens in the body to help keep the cancer from growing or spreading. Eventually, metastatic prostate cancer (cancer that has spread) develops a resistance to hormone therapy, meaning the treatment stops working to control the cancer's growth.
Researchers found that continuing bevacizumab (Avastin) while switching the chemotherapy used for second-line treatment lengthened the lives of patients with metastatic (cancer that has spread) colorectal cancer who had already received bevacizumab and another type of chemotherapy, a new study showed. Second-line treatment is treatment given after the first treatment, called first-line treatment, has stopped working. This approach has been used in the United States, and this study confirms its use as an effective treatment method.
A large national survey of people with cancer showed that a patient's income strongly predicts whether he or she will participate in a clinical trial. A clinical trial is a research study involving people. A clinical trial may focus on new treatments, new methods to prevent cancer, and ways to manage the symptoms and side effects of cancer and cancer treatment.
According to a recent study, giving bevacizumab (Avastin) along with standard chemotherapy doubled the time it took for platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers to worsen. These are all cancers of a woman's reproductive system that are treated similarly. Platinum-based chemotherapy is often the first treatment for these cancers and includes the drugs cisplatin (Platinol), carboplatin (Paraplat, Paraplatin), and oxaliplatin (Eloxatin). When platinum-based drugs stop working to control the cancer's growth, it is called platinum-resistant cancer.
A recent study showed that patients with metastatic kidney cancer (kidney cancer that has spread to other parts of the body) preferred pazopanib (Votrient) to sunitinib (Sutent), reporting that they had better quality of life while receiving pazopanib. These drugs are a type of treatment called targeted therapy, which targets the cancer's specific genes, proteins, or tissue environment that contributes to cancer growth and survival. To help control cancer growth, patients with metastatic kidney cancer often need to take one of these drugs for many months or years. This means that they are also likely to experience side effects for as long as they take the drug, which can greatly affect their long-term quality of life.
In a new study on a type of leukemia called high-risk B-precursor acute lymphoblastic leukemia (ALL), researchers found that adolescents and young adults (ages 16 to 30) were more likely to have the disease recur (come back after treatment) and more likely to die from the disease than younger patients. Adolescents and young adults (often shortened to AYA) with cancer make up a unique group of patients with different medical, social, and emotional needs than both younger and older patients. The results of this study highlight the importance of finding new ways to treat leukemia and lower the side effects of treatment for these patients.
A new immunotherapy (called BMS-936558) helped shrink melanoma, kidney cancer, and non-small cell lung cancer (NSCLC) in a recent early study. Immunotherapy is designed to boost the body's natural defenses to fight the cancer. It uses materials either made by the body or in a laboratory to bolster, target, or restore immune system function.
A recent study showed that the drug olanzapine (Zyprexa) helps manage nausea and vomiting from chemotherapy when the usual treatments for these side effects are not working. Nausea and vomiting is a common, but often manageable, side effect of chemotherapy. However, despite treatments given to prevent nausea and vomiting, about 30% to 40% of patients taking certain types of chemotherapy still have nausea and vomiting. When this happens, it is called breakthrough nausea and vomiting.
About one-third of men with localized, high-risk prostate cancer who received the drug abiraterone (Zytiga) along with hormone therapy before surgery had little to no cancer remaining after six months of treatment, according to a recent clinical trial. Prostate cancer is called localized high-risk prostate cancer when the tumor has grown throughout the prostate, is high grade (meaning the cancer cells barely look like normal cells, called a Gleason score of 8), and the man has a prostate-specific antigen (PSA) level higher than 20.